nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2013 | Original Paper

Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer

verfasst von: Hong-Fei Ji, Da Pang, Song-Bin Fu, Yan Jin, Lei Yao, Ji-Ping Qi, Jing Bai

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to investigate whether focal adhesion kinase (FAK) overexpression correlates with lymph node metastases and prognosis.

Methods

The protein expression of FAK was investigated in 153 paraffin-embedded tissues by immunohistochemical analysis and then correlated with various clinicopathologic parameters. FAK mRNA level was detected with quantitative RT-PCR in 57 NSCLC frozen tissues and 20 normal matched tissues.

Results

Immunohistochemistry showed FAK overexpression was significantly associated with positive lymph node metastasis and more advanced disease stage of NSCLCs and adenocarcinoma subtype; real-time PCR also indicated a statistically significant correlation between increased FAK mRNA level and the presence of nodal metastases. Moreover, in survival analysis, FAK overexpression was significantly associated with worse overall survival.

Conclusions

FAK overexpression is a promising pathological factor to predict aggressive behavior and prognosis in patients with NSCLC, particularly in the adenocarcinoma subtype.

Benlimame N, He Q, Jie S et al (2005) FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 171:505–516PubMedCrossRef

Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of prognosis. Chest 122:1037–1057PubMedCrossRef

Carelli S, Zadra G, Vaira V, et al (2006) Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer. 53(3):263–71

Dunn KB, Heffler M, Golubovskaya VM (2010) Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem 10:722–734PubMedCrossRef

Evan G (2010) Getting one’s Fak straight. Dev Cell 19:185–186PubMedCrossRef

Frame MC, Patel H, Serrels B et al (2010) The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol 11:802–814PubMedCrossRef

Garces CA et al (2006) Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 66:1446–1454PubMedCrossRef

Golubovskaya VM, Conway-Dorsey K, Edmiston SN et al (2009a) FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 125:1735–1738PubMedCrossRef

Golubovskaya VM, Kweh FA, Cance WG (2009b) Focal adhesion kinase and cancer. Histol Histopathol 24:503–510PubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRef

Hirsch FR, Spreafico A, Novello S et al (2008) The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 3:1468–1481PubMedCrossRef

Jemal A, Siegel R, Xu J et al (2010) Cancer statistics 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Kurio N, Shimo T, Fukazawa T et al (2011) Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo. Exp Cell Res 317:1134–1146PubMedCrossRef

Lesslie DP, Summy JM, Parikh NU et al (2006) Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 94:1710–1717PubMed

Ma WW (2011) Development of focal adhesion kinase inhibitors in cancer therapy. Anticancer Agents Med Chem 11:638–642PubMedCrossRef

McLean GW, Carragher NO, Avizienyte E et al (2005) The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 5:505–515PubMedCrossRef

Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6:449–458PubMedCrossRef

Meng XN, Jin Y, Yu Y et al (2009) Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101:327–334PubMedCrossRef

Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68PubMedCrossRef

Ocak S, Yamashita H, Udyavar AR et al (2010) DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29:6331–6342PubMedCrossRef

Ocak S, Chen H, Callison C et al (2012) Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer 118:1293–1301PubMedCrossRef

Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef

Provenzano PP, Keely PJ (2009) The role of focal adhesion kinase in tumor initiation and progression. Cell Adh Migr 3:347–350PubMedCrossRef

Roberts WG, Ung E, Whalen P et al (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935–1944PubMedCrossRef

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRef

Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14:77–94PubMedCrossRef

Shibue T, Weinberg RA (2009) Integrin beta1-focal adhesion kinase signalin2010 g directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 106:10290–10295PubMedCrossRef

Sieg DJ, Hauck CR, Ilic D et al (2000) FAKintegrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256PubMedCrossRef

Slack-Davis JK, Martin KH, Tilghman RW et al (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282:14845–14852PubMedCrossRef

Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5:206–219PubMedCrossRef

Tomar A, Schlaepfer DD (2010) A PAK-activated linker for EGFR and FAK. Dev Cell 18:170–172PubMedCrossRef

Walsh C, Tanjoni I, Uryu S et al (2010) Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 9:778–790PubMedCrossRef

Webb DJ, Donais K, Whitmore LA et al (2004) FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 6:154–161PubMedCrossRef

Zheng D, Golubovskaya V, Kurenova E et al (2010) A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol Carcinog 49:200–209PubMed

Titel: Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer
verfasst von: Hong-Fei Ji
Da Pang
Song-Bin Fu
Yan Jin
Lei Yao
Ji-Ping Qi
Jing Bai
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1342-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center

Mutation analysis of the SHFM1 gene in breast/ovarian cancer families

Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients

Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie